-+ 0.00%
-+ 0.00%
-+ 0.00%

Black Diamond Therapeutics turns to Q1 net loss of $9 million

PUBT·05/07/2026 11:24:21
Listen to the news
Black Diamond Therapeutics turns to Q1 net loss of $9 million
  • Black Diamond Therapeutics posted a Q1 net loss of USD 9 million, swinging from net income of USD 56.5 million a year earlier.
  • Cash, cash equivalents, and investments fell to USD 118.3 million from USD 128.7 million at Dec. 31, 2025; net cash used in operations was USD 10.2 million versus net cash provided by operations of USD 53.4 million a year earlier.
  • R&D expenses dropped to USD 7 million from USD 10.5 million, due to progression of Phase 2 silevertinib NSCLC trial and outlicensing of BDTX-4933 to increase focus on silevertinib.
  • G&A expenses declined to USD 4.3 million from USD 5 million, on continued operational efficiencies.
  • 2026 ASCO oral presentation of Phase 2 silevertinib data in frontline EGFRm NSCLC set for May 30; first patient dosed in Phase 2 trial in newly diagnosed EGFRvIII+ GBM, with cash runway expected into 2H 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Black Diamond Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001701541-26-000015), on May 07, 2026, and is solely responsible for the information contained therein.